share_log

Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination

Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination

輝瑞股票因肯尼迪擔任衛生與公衆服務部提名的資訊在11月下跌了10%
Benzinga ·  11/22 10:55

Pfizer Inc (NYSE:PFE) shares are trading lower by 10% to $25.13 in November and are near decade-lows after President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS).

輝瑞公司(紐交所:PFE)股價在11月份下跌了10%,至25.13美元,距離十年低位不遠,這是在當選總統特朗普上週宣佈打算提名羅伯特·F·肯尼迪擔任衛生及公衆服務部(HHS)部長後的情況。

The decision has heightened concerns over potential policy shifts in vaccine regulation and pharmaceutical oversight, areas central to Pfizer's business.

這一決定加劇了人們對疫苗監管和藥品監管政策轉變的擔憂,這些是輝瑞業務的核心領域。

What To Know: Kennedy, a known vaccine skeptic, has previously promoted discredited theories linking vaccines to autism. His appointment raises questions about the direction of U.S. health policy under Trump's administration, particularly regarding vaccine guidelines and FDA regulatory practices.

要了解的是:肯尼迪是衆所周知的疫苗懷疑論者,此前曾推動已被證實不實的理論,將疫苗與自閉症聯繫起來。他的任命引發了對特朗普政府衛生政策走向的質疑,特別是關於疫苗指南和FDA監管實踐。

Pfizer, a global leader in vaccine development with products like the Prevnar pneumonia vaccine and its groundbreaking COVID-19 vaccine, could face new challenges if Kennedy's policies alter vaccine recommendations or erode public trust.

作爲全球疫苗開發領導者,輝瑞擁有普列瓦爾肺炎疫苗等產品,以及開創性的COVID-19疫苗。如果肯尼迪的政策改變疫苗推薦或瓦解公衆信任,輝瑞可能面臨新挑戰。

Read Also: Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs

閱讀更多:隨着肯尼迪瞄準減肥藥概念,禮來股價大跌

In addition to vaccines, Pfizer's broader pharmaceutical operations, including its oncology, rare disease and cardiovascular drug segments, may also be affected by changes in FDA approval processes or drug pricing strategies under Kennedy's tenure. His criticism of pharmaceutical companies' influence over public health has fueled speculation about potential reforms targeting industry practices.

除疫苗外,輝瑞的更廣泛藥品業務,包括其腫瘤學、罕見疾病和心血管藥物領域,也可能受到FDA審批流程或肯尼迪任期下藥品定價策略變化的影響。他對製藥公司對公共衛生的影響的批評,引發了有關潛在改革針對行業實踐的推測。

Analysts warn that any major shifts in vaccine policy or regulatory frameworks could have far-reaching consequences for the pharmaceutical sector, with Pfizer among the most exposed.

分析師警告稱,任何疫苗政策或監管框架的重大轉變都可能對藥品行業產生深遠影響,而輝瑞是最容易受到影響的公司之一。

Read Also: Robert Kennedy Jr. Poised To Lead Health And Human Services: Why FDA, NIH Officials Are Nervous

閱讀更多:羅伯特·肯尼迪即將領導衛生及公衆服務部:爲什麼FDA、NIH官員感到緊張

How To Buy PFE Stock

如何購買輝瑞股票

By now you're likely curious about how to participate in the market for Pfizer – be it to purchase shares, or even attempt to bet against the company.

現在你可能對如何參與輝瑞公司的市場感到好奇,無論是購買股票,還是嘗試對該公司進行博弈。

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

通常是通過券商帳戶購買股票。您可以在此處找到可能的交易平台列表。許多平台將允許您購買「碎股」,這樣就可以擁有部分股票而無需購買整個股票。例如,某些股票,如伯克希爾哈撒韋(Berkshire Hathaway),可能需要支付數千美元才能擁有一股。但是,如果您只想投資一部分股票,券商將允許您這樣做。

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

如果您想押注股票下跌,流程就更爲複雜了。您需要訪問期權交易平台,或者找一家券商讓您通過借出股票進行「開空」操作(借股出售)。您可以在該資源中了解到賣空股票的過程。否則,如果您的券商允許您交易期權,您可以在當前股票交易價以上的執行價上購買看跌期權或者賣出看漲期權 - 無論哪種情況都可以讓您從股票價格下跌中獲利。

According to data from Benzinga Pro, PFE has a 52-week high of $31.54 and a 52-week low of $24.48.

根據Benzinga Pro的數據,輝瑞的52周最高價爲31.54美元,52周最低價爲24.48美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論